Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has reported Total Debt for 9 consecutive years, with $121.3 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Total Debt changed N/A year-over-year to $121.3 million; the trailing twelve-month figure through Sep 2025 stood at $121.3 million (changed N/A YoY), and the FY2024 full-year result was $93.8 million, changed N/A from the prior year.
• Total Debt steadied at $121.3 million in Q3 2025 per ALNY's latest filing, from $120.8 million in the prior quarter.
• Across five years, Total Debt topped out at $677.7 million in Q2 2022 and bottomed at $93.8 million in Q4 2024.
• Historically, Total Debt has averaged $354.3 million across 4 years, with a median of $312.4 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Total Debt soared 253.25% in 2021, then jumped 56.46% in 2022.
• Over 4 years, Total Debt stood at $675.7 million in 2021, then gained by 0.3% to $677.7 million in 2022, then tumbled by 86.16% to $93.8 million in 2024, then climbed by 29.32% to $121.3 million in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $121.3 million, $120.8 million, and $118.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.